Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
Mid-term results of the first clinical trial designed specifically to evaluate the safety and effectiveness of two cell therapies that are showing early promise in treating angiitis-induced critical limb ischemia were released today in STEM CELLS Translational Medicine.
In the first human clinical trial, researchers at Massachusetts General Hospital and surgeons at Beth Israel Deaconess Medical Center have validated the practicality and accuracy of an oxygen-sensing liquid bandage that measures the concentration of oxygen in transplanted tissue
An interim analysis from the Swedish Drug-Elution Trial in Peripheral Arterial Disease (SWEDEPAD) has now been presented.
People who have coronary artery disease, stroke or peripheral artery disease often are prescribed a statin, a cholesterol-lowering drug that reduces the risk of heart attack or stroke.
People with heart disease can receive either the high-dose or standard-dose flu vaccines for protection from heart or lung-related deaths or hospitalizations, according to late breaking research presented today at the American Heart Association's Scientific Sessions 2020.
One of the most harrowing effects of COVID-19 is severe damage to the lungs, which makes breathing hard or impossible for those who're severely affected.
A study recently published in the journal Circulation looks at temporal trends in the burden of comorbidities and associated risk of mortality among patients with heart failure (HF) with preserved ejection fraction (HFpEF), in which the left ventricle of the heart is not able to relax enough to fill properly with blood, and HF with reduced ejection fraction (HFrEF), in which the left ventricle is not able contract enough to pump out as much blood.
Heart failure posed the greatest 5-year risk of death for people newly diagnosed with Type 2 diabetes than any other heart or kidney disease, according to new research published today in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
The COVID-19 pandemic has been found to cause disproportionate harm in patients with cardiovascular disease, especially among the elderly population, among other risk factors. However, a new study published on the preprint server medRxiv* in June 2020 is the first to report its clinical features in patients with aortic stenosis who have had a transcatheter aortic valve replacement (TAVR).
A new study has shown that anticardiolipin antibodies are associated with the novel coronavirus infection or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19.
Pairing a blood-thinning drug with aspirin daily for patients who have an angioplasty with a stent can contribute to better health outcomes, including lower risk of death, than aspirin alone, according to a recent study by cardiologists at the University of Alberta and Mazankowski Alberta Heart Institute.
Lower extremity artery disease is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people.
In regenerative medicine, an ideal treatment for patients whose muscles are damaged from lack of oxygen would be to invigorate them with an injection of their own stem cells.
The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.
People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation
A team of researchers at the University of Minnesota Medical School recently proved the ability to grow human-derived blood vessels in a pig--a novel approach that has the potential for providing unlimited human vessels for transplant purposes.
Researchers from the Boston University School of Medicine have conclusively found that increased time spent leading a healthy lifestyle during midlife can keep certain diseases at bay and promote good cardiovascular health.
Novel biomedical advances that show promise in the lab often fall short in clinical trials. For researchers studying peripheral artery disease, this is made more difficult by a lack of standardized metrics for what recovery looks like.
Someday, according to a new study, doctors might prescribe chocolate or cocoa to help patients with peripheral arterial disease to walk easier. The study published in February 2020 in the journal Circulation Research of the American Heart Association (AHA) reports a significant improvement in walking distance in patients following regular cocoa consumption.